At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $198M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 30.06.2020 | 5AM Ventur... | 5amventure... |
| 13.01.2022 | Medivate P... | medivatepa... |
| - | LINEA Inve... | lineainves... |
| - | RA Capital... | racap.com |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.03.2021 | Series B | $120M | - |
| 30.06.2020 | Series A | $78M | - |
Mentions in press and media 16
| Date | Title | Description |
| 18.07.2024 | Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering | SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimm... |
| 18.07.2024 | Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering | SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimm... |
| 02.03.2021 | Artiva Biotherapeutics Raises $120M in Series B | SAN DIEGO, CA, Artiva Biotherapeutics, an oncology-focused biopharmaceutical company, announced the closing of a $120M Series B led by Venrock Healthcare. >> Click here for more funding data on Artiva Biotherapeutics >> To e... |
| 02.03.2021 | Artiva Biotherapeutics has raised a $120M Series B round led by Venrock Healthcare | - |
| 01.03.2021 | Daily funding roundup - March 1st, 2021 | Skydio raised $170M; Artiva landed $120M; FogPharma secured $107M; Axonius picks up $100M Skydio: Skydio is a Redwood City, Ca.-based autonomous drone-maker. Skydio has raised $170 million in Series D funding at a post-money valuation of mo... |
| 01.03.2021 | Artiva Biotherapeutics Finds $120M In Series B | San Diego-based biopharmaceuticals company Artiva Biotherapeutics has raised a big, $120M funding round, in its Series B funding, according to the company. The funding was led by Venrock Healthcare Capital Partners, and also included Acuta ... |
| 26.02.2021 | Artiva, fresh from Merck pact, raises $120M for NK therapy R&D | Artiva Biotherapeutics has raised $120 million to advance a pipeline of allogeneic natural killer (NK) cell therapies. The Merck-partnered biotech has an unmodified NK cell therapy in the clinic and a clutch of CAR-engineered candidates fol... |
| 26.02.2021 | Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors | On February 26, 2021, Artiva Biotherapeutics, Inc. closed the transaction. The company raised funding led by by new investor Venrock Healthcare Capital Partners, a fund managed by Venrock. The transaction included participation from other n... |
| 26.02.2021 | Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies | - |
| 26.02.2021 | Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies | SAN DIEGO--(BUSINESS WIRE)--Feb 26, 2021-- Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their abilit... |
Show more